CD8A and glioblastoma: To explore this possibility, we used a modified ovalbumin (OVA)/OT-1 model system, whereby GL261 GBM cells were engineered to express OVA, which rendered them susceptible to recognition and killing by OVA antigen-specific CD8α+ T cells derived from OT-1 transgenic mice (68).